Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Autoimmune Disorders

  Free Subscription


31.05.2021

1 Acta Neurol Scand
3 Ann Neurol
3 BMC Neurol
1 Curr Treat Options Neurol
1 Diabetes
4 Diabetes Res Clin Pract
1 Intern Med
3 J Autoimmun
1 J Immunol
11 J Neuroimmunol
3 J Neurol
1 J Pediatr
1 Kidney Int
1 Lancet Neurol
8 Mult Scler
4 N Engl J Med
1 Nat Rev Neurol
7 Neurology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Neurol Scand

  1. LANDTBLOM AM, Berntsson SG, Bostrom I, Iacobaeus E, et al
    Multiple sclerosis and COVID-19: The Swedish experience.
    Acta Neurol Scand. 2021 May 24. doi: 10.1111/ane.13453.
    PubMed         Abstract available


    Ann Neurol

  2. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    PubMed         Abstract available

  3. DE BRUIJN MAAM, Bastiaansen AEM, Mojzisova H, van Sonderen A, et al
    The Antibodies Contributing to focal Epilepsy Signs and symptoms (ACES) score.
    Ann Neurol. 2021 Jan 11. doi: 10.1002/ana.26013.
    PubMed         Abstract available

  4. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    PubMed         Abstract available


    BMC Neurol

  5. WEN H, Jin D, Cai L, Wu T, et al
    Neurobrucellosis with ischemic stroke and spinal cord involvement: a case report.
    BMC Neurol. 2021;21:129.
    PubMed         Abstract available

  6. WANG Y, Wu X, Lu B
    Improvement in mild anti-IgLON5 encephalopathy without immunotherapy: a case report.
    BMC Neurol. 2021;21:120.
    PubMed         Abstract available

  7. NATSUI H, Takahashi M, Nanatsue K, Itaya S, et al
    Mother and son cases of Bickerstaff's brainstem encephalitis and fisher syndrome with serum anti-GQ1b IgG antibodies: a case report.
    BMC Neurol. 2021;21:130.
    PubMed         Abstract available


    Curr Treat Options Neurol

  8. SIMPSON A, Mowry EM, Newsome SD
    Early Aggressive Treatment Approaches for Multiple Sclerosis.
    Curr Treat Options Neurol. 2021;23:19.
    PubMed         Abstract available


    Diabetes

  9. HALLER MJ, Jacobsen LM, Posgai AL, Schatz DA, et al
    How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?
    Diabetes. 2021 Feb 25. pii: dbi20-0045. doi: 10.2337/dbi20-0045.
    PubMed         Abstract available


    Diabetes Res Clin Pract

  10. SERDAROVA M, Dimova R, Chakarova N, Grozeva G, et al
    Relationship between cardiac autonomic neuropathy and cardio-metabolic risk profile in adults with type 1 diabetes.
    Diabetes Res Clin Pract. 2021;174:108721.
    PubMed         Abstract available

  11. HILLIARD ME, Marrero DG, Minard CG, Cao VT, et al
    Design and psychometrics for new measures of health-related quality of life in adults with type 1 diabetes: Type 1 Diabetes and Life (T1DAL).
    Diabetes Res Clin Pract. 2021;174:108537.
    PubMed         Abstract available

  12. VRACHATIS DA, Papathanasiou KA, Kossyvakis C, Giotaki SG, et al
    Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence.
    Diabetes Res Clin Pract. 2021;174:108724.
    PubMed         Abstract available

  13. KROGER J, Siegmund T, Schubert-Olesen O, Keuthage W, et al
    AGP and Nutrition - Analysing postprandial glucose courses with CGM.
    Diabetes Res Clin Pract. 2021;174:108738.
    PubMed         Abstract available


    Intern Med

  14. AYAKI M, Manabe N, Fujita M, Katsumata R, et al
    Prevalence of Autoimmune Disease in Patients with Eosinophilic Esophagitis: A Cross-sectional Study of Three Hospitals in Japan.
    Intern Med. 2021 May 22. doi: 10.2169/internalmedicine.7389.
    PubMed         Abstract available


    J Autoimmun

  15. TAKESHITA M, Suzuki K, Nakazawa M, Kamata H, et al
    Antigen-driven autoantibody production in lungs of interstitial lung disease with autoimmune disease.
    J Autoimmun. 2021;121:102661.
    PubMed         Abstract available

  16. NISHIMURA T, Okayasu T, Hosoi H, Kitahara T, et al
    Long-term (16-26 years) follow-up outcome of steroid therapy in refractory autoimmune sensorineural hearing loss.
    J Autoimmun. 2021;121:102664.
    PubMed         Abstract available

  17. KJELDSEN J, Nielsen J, Ellingsen T, Knudsen T, et al
    Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark.
    J Autoimmun. 2021;120:102632.
    PubMed         Abstract available


    J Immunol

  18. SCHELL SL, Bricker KN, Fike AJ, Chodisetti SB, et al
    Context-Dependent miR-21 Regulation of TLR7-Mediated Autoimmune and Foreign Antigen-Driven Antibody-Forming Cell and Germinal Center Responses.
    J Immunol. 2021 May 26. pii: jimmunol.2001039. doi: 10.4049/jimmunol.2001039.
    PubMed         Abstract available


    J Neuroimmunol

  19. FINSTERER J, Scorza FA, Scorza CA, Fiorini AC, et al
    Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies.
    J Neuroimmunol. 2021;357:577609.
    PubMed        

  20. CHOUDHARY A, Bhargava A, Khichar S, Pradhan S, et al
    Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - A prospective study from Northwest India.
    J Neuroimmunol. 2021;351:577456.
    PubMed         Abstract available

  21. AKAISHI T, Misu T, Takahashi T, Takai Y, et al
    Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.
    J Neuroimmunol. 2021;351:577467.
    PubMed         Abstract available

  22. DU Q, Shi Z, Chen H, Zhang Y, et al
    Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2021;353:577494.
    PubMed         Abstract available

  23. FANG F, Wang Y, Xu W
    Anti-N-methyl-d-aspartate receptor encephalitis associated with intracranial cryptococcal infection: A case report and 2-year follow-up.
    J Neuroimmunol. 2021;353:577502.
    PubMed         Abstract available

  24. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed         Abstract available

  25. LI C, Wang J, Sun X, Li R, et al
    The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China.
    J Neuroimmunol. 2021;353:577506.
    PubMed         Abstract available

  26. ZHANG H, Yang Y, Luo X
    Anti-MOG antibodies associated demyelination following encephalomeningitis: Case report.
    J Neuroimmunol. 2021;353:577519.
    PubMed         Abstract available

  27. WANG J, Qiu Z, Li D, Dong H, et al
    Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review.
    J Neuroimmunol. 2021;353:577515.
    PubMed         Abstract available

  28. WANG T, Wang B, Zeng Z, Li H, et al
    Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.
    J Neuroimmunol. 2021;354:577527.
    PubMed         Abstract available

  29. MANOUCHEHRI N, Guisso DR, Hussain RZ, Minassian BA, et al
    The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo.
    J Neuroimmunol. 2021;354:577544.
    PubMed         Abstract available


    J Neurol

  30. HOU Y, Shao K, Yan Y, Dai T, et al
    Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.
    J Neurol. 2021 May 21. pii: 10.1007/s00415-021-10621.
    PubMed         Abstract available

  31. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    PubMed         Abstract available

  32. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    PubMed         Abstract available


    J Pediatr

  33. ASHKENAZI L, Hashkes PJ
    50 Years Ago in TheJournalofPediatrics: DNA Antibody Testing for Childhood Systemic Lupus Erythematosus (cSLE): Going Far(r).
    J Pediatr. 2021;233:104.
    PubMed        


    Kidney Int

  34. TAN HZ, Tan RY, Jun Choo JC, Lim CC, et al
    Is COVID-19 Vaccination unmasking Glomerulonephritis?
    Kidney Int. 2021 May 22. pii: S0085-2538(21)00504.
    PubMed        


    Lancet Neurol

  35. MORGAN J
    Amit Bar-Or: breaking new ground in multiple sclerosis.
    Lancet Neurol. 2021;20:421.
    PubMed        


    Mult Scler

  36. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    PubMed         Abstract available

  37. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    PubMed         Abstract available

  38. HOHLFELD R
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
    PubMed        

  39. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
    PubMed        

  40. MCMURRAN CE
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
    PubMed        

  41. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    PubMed         Abstract available

  42. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    PubMed         Abstract available

  43. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    PubMed         Abstract available


    N Engl J Med

  44. FRALICK M, Sarma S
    Thyrotoxic Periodic Paralysis.
    N Engl J Med. 2021;384:e71.
    PubMed        

  45. CHANDWAR K
    Avacopan for the Treatment of ANCA-Associated Vasculitis.
    N Engl J Med. 2021;384:e81.
    PubMed        

  46. MATSUO Y, Miyabe Y
    Avacopan for the Treatment of ANCA-Associated Vasculitis.
    N Engl J Med. 2021;384:e81.
    PubMed        

  47. JAYNE DRW, Merkel PA, Bekker P
    Avacopan for the Treatment of ANCA-Associated Vasculitis. Reply.
    N Engl J Med. 2021;384:e81.
    PubMed        


    Nat Rev Neurol

  48. FOX RJ
    How common is active inflammation in progressive multiple sclerosis?
    Nat Rev Neurol. 2021 May 25. pii: 10.1038/s41582-021-00518.
    PubMed        


    Neurology

  49. TOOSY AT, Kapur K, Nair KV
    Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
    Neurology. 2021;96:927-928.
    PubMed        

  50. FOX RJ, Kryscio RJ
    A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
    Neurology. 2021;96:833-834.
    PubMed        

  51. KOCH MW, Sage K, Kaur S, Kim J, et al
    Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Neurology. 2021;96:e2313-e2322.
    PubMed         Abstract available

  52. BAR-OR A, Herman A, Stokmaier D
    Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    PubMed        

  53. HAHN N
    Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    PubMed        

  54. SIEGLER JE, Galetta S
    Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:869.
    PubMed        

  55. SAN MARTIN AH, Cuadrado CA, Arbizu MG, Rabano-Suarez P, et al
    Autoimmune Septin-5 Disease Presenting as Spinocerebellar Ataxia and Nystagmus.
    Neurology. 2021 May 24. pii: WNL.0000000000012240.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: